Imported generics have so far managed to escape Trump’s glare likely due to their critical role in keeping US healthcare costs in check. However, Indian pharma is not waiting for the axe to fall, and experts say a multi-pronged defence strategy by key players is already in motion.
The diktat could be positive for local generic drug companies
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1960 in its research report dated September 23, 2025.
Exports from Halol manufacturing plant continue to be restricted
The US government has long sought to shift pharmaceutical manufacturing back to domestic soil, citing both economic and national security concerns.
Motilal Oswal is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 1960 in its research report dated July 31, 2025.
Brokerage Investec downgraded Sun Pharma shares by two notches to 'sell' while Choice Equity Broking gave an 'Add' rating
Trump's letters to 17 of the world’s biggest pharmaceutical majors has stated that companies should immediately lower charges for existing drugs, and furnish guarantee that future medicines be launched at par with what other countries are paying.
Sun Pharmaceuticals share price: India business is expected to grow 10 to 12 percent YoY, driven by volume gains, in-licensing deals, and new launches.
Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.
Sun Pharma share price: Morgan Stanley projects Leqselvi sales at $61 million for FY26 and about $83 million for FY27.
'A renewed push for 'Buy America' could complicate matters for low-margin generics, and any uptick in regulatory stringency may weigh on sentiment,' said an analyst.
In FY25 alone, the cash pile increased by over Rs 10,200 crore, underscoring a decisive shift in the capital allocation priorities of India’s drugmakers
Pharma stocks: The Nifty Pharma index plunged nearly 2% to close as the top sectoral loser after Trump's statement.
Kirti Ganorkar will succeed founder Dilip Shanghvi as managing director (MD) of the company
Sun Pharma bagged eight observations from the US-based regulatory agency US FDA, following an observation at its Halol plant in Gujarat.
As Executive Chairman, Shanghvi will focus on strengthening Sun Pharma's high-growth specialty portfolio and will provide strategic oversight for the company's long-term strategy.
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 2000 in its research report dated May 23, 2025.
The company's board has declared a final dividend of Rs 5.50 per share for the FY25, while 7th July 2025 is fixed as the record date.
Analysts said that the US President Trump’s latest executive order on drug price control could indirectly discourage Indian drug makers from pursuing specialty business in America.
The new regulation appears to be less disruptive for the Indian generics; may impact those having exposure to speciality/patented portfolios
Pharma players working on speciality/patented portfolios could be impacted more
Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated April 10, 2025.